Currently, no markers for breast cancer screening or detection are in clinical use, but a few markers, e.g. carcinoembryonic antigen (CEA), or carbohydrate antigens 15–3 and 27.29, are being used and seem helpful for making decisions in the metastatic [9] or surveillance [10] setting. Here, CEACAM5 is linked to breast carcinoma.